中樞神經系統特異性反義寡核甘酸市場:規模，佔有率，預測，機會分析(2022年～2028年)

本報告提供全球中樞神經系統特異性反義寡核甘酸市場相關調查，提供市場概要，以及藥物，各適應症，各流通管道，各地區的趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 調查目的·前提條件

第2章 市場展望

• 報告的說明
• 摘要整理
  • 市場明細:各藥物
  • 市場明細:各適應症
  • 市場明細:各流通管道
  • 市場明細:各地區
• 連貫機遇地圖(COM)

第3章 市場動態，法規，及趨勢分析

• 市場動態
  • 促進因素
  • 阻礙因素
  • 市場機會
• 影響分析
• 開發平台分析
• 償付方案
• 流行病學
• PEST分析

第4章 全球中樞神經系統特異性反義寡核甘酸市場:藥物，2017年～2028年，(100萬美元)

• 簡介
• 已通過核准
• 開發平台(管線)

第5章 全球中樞神經系統特異性反義寡核甘酸市場:各適應症，2017年-2028年，(100萬美元)

• 簡介
• 遺傳性轉甲狀腺素蛋白澱粉樣變性(hATTR)/多發性神經病變
• 脊髓性肌萎縮症
• 亨丁頓舞蹈症

第6章 全球中樞神經系統特異性反義寡核甘酸市場:各流通管道，2017年～2028年，(100萬美元)

• 簡介
• 院內藥局
• 零售藥局
• 線上藥局

第7章 全球中樞神經系統特異性反義寡核甘酸市場:各地區，2017年-2028年，(100萬美元)

• 簡介
• 北美
• 南美
• 歐洲
• 亞太地區
• 中東
• 非洲

第8章 競爭情形

• 熱圖分析
• 企業簡介
  • Alnylam Pharmaceuticals Inc.
  • Sarepta Therapeutics Inc.
  • Biogen Inc.
  • Ionis Pharmaceuticals Inc.
  • Wave Life Sciences Ltd.
  • Stroke Therapeutic Inc.
  • Dynacure
  • ProQR Therapeutics NV
  • Q-STATE BIOSCIENCES, INC.
• 分析師的見解

第9章 章節

Antisense oligonucleotides are synthetic strings of nucleic acid, which reduce expression of messenger RNA (m-RNA). The function performed by interference with pre m- RNA splicing are restoration of protein and modification of protein. Antisense oligonucleotide is a new approach to treat several neurodegenerative disorders to prevent disease onset or stop disease development.

Market Dynamics

Increasing prevalence of neurodegenerative disease is a major factor driving CNS specific antisense oligonucleotide market growth. According to fact sheet from Alzheimer Association, an estimated around 5.7 million Americans were diagnosed with Alzheimer's dementia in 2018. Moreover, rich product pipeline for the treatment of CNS disorders and rare diseases associated with it is expected to boost the market growth. For instance, in December 2018, Biogen and Ionis Pharmaceuticals product IONIS-SOD1Rx (BIIB067) cleared Phase 1 clinical trial and is expected to be launched by 2020.

Key features of the study:

• This report provides in-depth analysis of the CNS specific antisense oligonucleotide market and provides market size (US$ million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2022-2028), considering 2021, as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by key players
• It profiles key players in the global CNS specific antisense oligonucleotide market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study include, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Biogen Inc., Ionis Pharmaceuticals Inc., Wave Life Sciences Ltd., Stroke Therapeutic Inc., Dynacure, ProQR Therapeutics N.V., Q-STATE BIOSCIENCES, INC.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
• The global CNS specific antisense oligonucleotide market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the CNS specific antisense oligonucleotide market

Detailed Segmentation:

• Global CNS Specific Antisense Oligonucleotide Market, By Drug:
  • Approved
    • Patisiran
    • Nusinersen
    • Inotersen
  • Pipeline
    • IONIS-HTT Rx (RG6042)
• Global CNS Specific Antisense Oligonucleotide Market, By Indication:
  • Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
  • Spinal Muscular Atrophy
  • Huntington's Disease
• Global CNS Specific Antisense Oligonucleotide Market, By Distribution Channel:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
• Global CNS Specific Antisense Oligonucleotide Market, By Geography:
  • North America
    • By Drug:
    • Approved
    • Patisiran
    • Nusinersen
    • Inotersen
    • Pipeline
    • IONIS-HTT Rx (RG6042)
    • By Indication:
    • Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
    • Spinal Muscular Atrophy
    • Huntington's Disease
    • By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
    • By Country:
    • U.S.
    • Canada
  • Latin America
    • By Drug:
    • Approved
    • Patisiran
    • Nusinersen
    • Inotersen
    • Pipeline
    • IONIS-HTT Rx (RG6042)
    • By Indication:
    • Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
    • Spinal Muscular Atrophy
    • Huntington's Disease
    • By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
    • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • By Drug:
    • Approved
    • Patisiran
    • Nusinersen
    • Inotersen
    • Pipeline
    • IONIS-HTT Rx (RG6042)
    • By Indication:
    • Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
    • Spinal Muscular Atrophy
    • Huntington's Disease
    • By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
    • By Country:
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • By Drug:
    • Approved
    • Patisiran
    • Nusinersen
    • Inotersen
    • Pipeline
    • IONIS-HTT Rx (RG6042)
    • By Indication:
    • Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
    • Spinal Muscular Atrophy
    • Huntington's Disease
    • By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
    • By Country:
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • By Drug:
    • Approved
    • Patisiran
    • Nusinersen
    • Inotersen
    • Pipeline
    • IONIS-HTT Rx (RG6042)
    • By Indication:
    • Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
    • Spinal Muscular Atrophy
    • Huntington's Disease
    • By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
    • By Country:
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • By Drug:
    • Approved
    • Patisiran
    • Nusinersen
    • Inotersen
    • Pipeline
    • IONIS-HTT Rx (RG6042)
    • By Indication:
    • Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
    • Spinal Muscular Atrophy
    • Huntington's Disease
    • By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
    • By Country:
    • South Africa
    • Central Africa
    • North Africa
• Company Profiles
  • Alnylam Pharmaceuticals Inc.*
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Key Highlights
    • Market Strategies
  • Sarepta Therapeutics Inc.
  • Biogen Inc.
  • Ionis Pharmaceuticals Inc.
  • Wave Life Sciences Ltd.
  • Stroke Therapeutic Inc.
  • Dynacure
  • ProQR Therapeutics N.V.
  • Q-STATE BIOSCIENCES, INC.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug
  • Market Snippet, By Indication
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Pipeline Analysis
• Reimbursement Scenario
• Epidemiology
• Pest Analysis

4. Global CNS Specific Antisense Oligonucleotide Market, By Drug, 2017 - 2028, (US$ Mn)

• Introduction
  • Market Share Analysis, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
• Approved
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Patisiran
  • Nusinersen
  • Inotersen
• Pipeline
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • IONIS-HTT Rx (RG6042)

5. Global CNS Specific Antisense Oligonucleotide Market, By Indication, 2017 - 2028, (US$ Mn)

• Introduction
  • Market Share Analysis, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
• Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
• Spinal Muscular Atrophy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
• Huntington's Disease
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

6. Global CNS Specific Antisense Oligonucleotide Market, By Distribution Channel, 2017 - 2028, (US$ Mn)

• Introduction
  • Market Share Analysis, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
• Hospital Pharmacy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
• Retail Pharmacy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
• Online Pharmacy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

7. Global CNS Specific Antisense Oligonucleotide Market, By Region, 2017 - 2028, (US$ Mn)

• Introduction
  • Market Share Analysis, By Region, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, For Regions, 2017 - 2028
• North America
  • Market Size and Forecast, By Drug, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, By Indication, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
  • U.S.
  • Canada
• Latin America
  • Market Size and Forecast, By Drug, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, By Indication, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Europe
  • Market Size and Forecast, By Drug, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, By Indication, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • Market Size and Forecast, By Drug, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, By Indication, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of APAC
• Middle East
  • Market Size and Forecast, By Drug, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, By Indication, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
  • GCC
  • Israel
  • Rest of Middle East
• Africa
  • Market Size and Forecast, By Drug, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, By Indication, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
  • South Africa
  • Central Africa
  • North Africa

8. Competitive Landscape

• Heat Map Analysis
• Company Profiles
  • Alnylam Pharmaceuticals Inc.
  • Company Overview
  • Drug Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Sarepta Therapeutics Inc.
  • Company Overview
  • Drug Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Biogen Inc.
  • Company Overview
  • Drug Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Ionis Pharmaceuticals Inc.
  • Company Overview
  • Drug Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Wave Life Sciences Ltd.
  • Company Overview
  • Drug Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Stroke Therapeutic Inc.
  • Company Overview
  • Drug Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Dynacure
  • Company Overview
  • Drug Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • ProQR Therapeutics N.V.
  • Company Overview
  • Drug Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Q-STATE BIOSCIENCES, INC.
  • Company Overview
  • Drug Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
• Analyst Views

9. Section

• References
• Research Methodology
• About us and Sales Contact